THE EFFECT OF ARGININE AND GLUTAMINE ON COVID-19 PATIENTS OUTCOME: A RANDOMIZED CLINICAL TRIAL

Universitas Sriwijaya20 enrolled

Overview

The goal of this clinical trial is to determine effect of arginine and glutamine on outcome of COVID-19 patients. The main questions it aims to answer are: -to test the effect of oral nutritional supplements containing arginine and glutamine on covid-19 patients outcome Dr. M. Djamil General Hospital Padang Participants will given ONS containing arginine and glutamine. Researchers will compare intervention group with control group to see if ONS affected outcome of COVID-19 patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

COVID-19

Interventions

NeomuneDIETARY_SUPPLEMENT

Neomune containing 4.8 g arginine and 2 g glutamine

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients confirmed positive for COVID-19 * Age over 17 years * The patient can take food orally Exclusion Criteria: * Patients with restricted fluid intake * Patients who cannot take food orally * suffering from diabetes mellitus and kidney failure

Locations (1)

Dr. M. Djamil General Hospital

Padang, West Sumatera, Indonesia

Outcomes

Primary Outcomes

length of stay

length of stay of patients in hospital

Time frame: 3 months

Outcome

Outcome Measures of patients (discharge or dead)

Time frame: 3 months

ICU Admission

A patient is likely to be admitted to ICU during intervention period

Time frame: 3 months

Secondary Outcomes

Il-6 and CRP Levels

Il-6 and CRP Levels during hospitalization

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.